Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...

Here are key takeaways from latest research and a session of the European Association of the Study of Diabetes (EASD) ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Novo Nordisk (NVO) stock rises after full results from an early-stage trial of weight-loss pill amycretin. Read more here.

A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having its dreams dashed amid new trials ...

Incretin therapies based on GLP-1 receptor agonism aid in the loss of weight in obesity, but a relevant part of this loss (25%-40%) is attributed to loss of lean muscle mass, which raises the risk of ...

Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an ...

We need to take stock of the promises and limitations of new “miracle” weight loss drugs and treat the cause of weight gain, ...

Data from the US FDA's Adverse Event Reporting System on tirzepatide showed adverse events generally consistent with those ...

In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...

On the heels of disappointing low-dose data results, Zealand Pharma is back with separate findings for its GLP-1/GLP-2 ...